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Introduction
We have previously found decreased expression of glutamate transporters in the brain in schizophrenia and we hypothesize that abnormalities in glutamate reuptake contribute to the pathophysiology of this illness [1] . One novel mechanism for the regulation of glutamate transporter expression and activity involves the equilibrative nucleoside transporter type 1 (ENT1). ENT1 facilitates transport of nucleosides, such as adenosine, across biological membranes [2] [3] [4] . ENT1 transports adenosine until the concentration of adenosine is equalized on each side of the membrane. Inhibition of ENT transport activity leads to elevated levels of adenosine and increased activation of presynaptic adenosine A1 receptors [5] . However, recent evidence also suggests a role for ENT1 in modulating glutamate levels. For example, inhibition or knockdown of ENT1 diminishes mRNA expression and glutamate transport activity of excitatory amino acid transporter 2 (EAAT2) [6] . Given this putative role for ENT1, we hypothesize that alterations of ENT1 expression may contribute to glutamatergic abnormalities in patients with schizophrenia. Thus, we examined expression of ENT1 protein in the superior temporal gyrus (STG) and anterior cingulate cortex (ACC) in patients with schizophrenia and a comparison group.
Materials and methods

Patients and tissue preparation
Patients from the Mount Sinai Medical Center brain bank were recruited prospectively and underwent a thorough antemortem diagnostic and clinical assessment ( Table 1) .
Patients were excluded for a history of alcoholism, death by suicide, or coma for more than 6 h before death. Next of kin consent was obtained for each patient. For western blot studies, STG and ACC were dissected, pulverized in liquid nitrogen, and stored at -801C. For immunofluorescence studies, prefrontal cortex was cryostat sectioned (15 mm) and mounted onto microscope slides which were stored at -801C.
Western blot analysis
Western blot samples were prepared and analyzed as previously described [7] . Homogenates were stored at -801C until analysis. ENT1 (1 : 600) and valosin-containing protein (VCP, 1 : 5000) antibodies were obtained from Abcam (Cambridge, Massachusetts, USA). Blots were imaged with the LiCor Odyssey laser-based imaging system. 
Data analysis
Using Odyssey 3.0 analytical software (LI-COR Biosciences, Lincoln, Nebraska, USA), near-infrared emissions detected by the LiCor Odyssey scanner were expressed as integrated intensity with top-bottom median intra-lane background subtraction. In each patient, duplicate lanes of ENT1 protein expression were normalized to VCP as an in-lane loading control and then averaged for each patient. VCP was chosen as a loading control because VCP was previously determined to be unchanged in schizophrenia compared with control individuals [8] .
Data were analyzed using Statistica (Statsoft, Tulsa, Oklahoma, USA). Correlation analyses were performed to probe for associations between the expression of ENT1 and tissue pH, age, and postmortem interval. One-way analysis of variance was used when significant correlations were not found. Analysis of variance was performed to assess the effects of antipsychotic medication exposure in patients with schizophrenia.
Results
To determine the localization of ENT1 in human brain, we performed immunofluorescence in sections from the prefrontal cortex (Fig. 1a ). ENT1 was expressed in large and small cells throughout the cortical gray matter. ENT1 expression colocalized with the neuronal marker NeuN in cells with large (pyramidal cell-like) and small (interneuron-like) profiles. ENT1 was also expressed in some small cells that were not stained with NeuN. We did not detect a fluorescent signal in sections stained with control antibodies (data not shown).
We found a significant decrease of ENT1 protein in the STG [F(1,46) = 7.52, P < 0.01], but not ACC, in patients with schizophrenia ( Fig. 1b) . No significant correlation was found between ENT1 expression and tissue pH, postmortem interval, or age. VCP protein expression in patients with schizophrenia was not changed compared with comparison patients. We did not find differences in ENT1 expression in patients with schizophrenia on antipsychotic medications at the time of death, compared with patients off medications for at least 6 weeks (data not shown).
Discussion
In this study, we demonstrated that ENT1 protein is expressed in neurons in the frontal cortex, consistent with reports that ENT1 is ubiquitously distributed in human tissue and expressed in neurons and astroglia in cortical regions [5, 9] . We also found that ENT1 protein expression was decreased in the STG in patients with schizophrenia. These findings support the hypothesis that nucleosidemediated neurotransmission may be abnormal in patients with schizophrenia, and suggest a mechanism for diminished glutamate reuptake capacity in this illness.
We speculate that diminished ENT1 expression could indirectly affect glutamate reuptake through changes in adenosine levels. Decreased ENT1 expression leads to accumulation of extracellular adenosine, which activates synaptic adenosine A1 receptors, diminishing presynaptic glutamate release [9, 10] . Decreased synaptic glutamate levels may lead to remodeling of synapses including a compensatory decrease in the expression of glutamate transporters such as EAAT2 [11] .
Alternatively, diminished ENT1 expression could directly affect glutamate reuptake in patients with schizophrenia. The glutamate transporter EAAT2 is localized to perisynaptic regions in astrocytic processes and linked to mitochondrial membranes through protein-protein interactions by several scaffolding proteins [12] . ENT1 is expressed in plasma and mitochondrial membranes, and may help stabilize the scaffolding protein complex that anchors EAAT2 in the plasma membrane. A decrease in ENT1 expression could disrupt this complex, leading to increased turnover and degradation of EAAT2 protein.
Regardless of the mechanism, decreased expression of ENT1 may contribute to the pathophysiology of schizophrenia. Changes in the levels of adenosine and/or glutamate in the synaptic cleft can affect NMDA-subtype glutamate receptor-mediated neuroplastic responses [10, 13] . Modulation of NMDA receptor function is a well-established pathway linked to symptoms in patients with schizophrenia, as NMDA receptor antagonists such as phencyclidine can cause schizophrenia-like symptoms in otherwise healthy patients [14, 15] .
We found decreased ENT protein expression in the STG, but not the ACC. Regionally divergent changes in gene expression are not without precedent. Several other studies have found changes in various gene expression products in one area, but not in another, suggesting that changes in the brain in schizophrenia are not global, but may be region specific [16] [17] [18] . Given that we only found modest changes in ENT1 expression in one brain region, our findings need to be carefully replicated in another schizophrenia sample.
Previous studies have suggested that antipsychotic medications might alter neurotransmitter transport [19, 20] . We did not detect any differences in ENT1 protein expression between medicated patients and patients who had been free of antipsychotic medications for 6 weeks before death, suggesting our findings are not due to a medication effect.
Conclusion
We found decreased expression of ENT1 protein in the STG in patients with schizophrenia. Taken together with our previous findings of altered glutamate transporter expression in this illness, these data support the hypothesis that diminished glutamate reuptake contributes to the pathophysiology of schizophrenia.
